TORONTO, Aug. 9 /CNW/ - Transition Therapeutics Inc. (“Transition” or the “Company”) (TSX: TTH), today announced that on August 9, 2007 it filed a business acquisition report (“BAR”) regarding the completion of its step acquisition of the issued and outstanding securities of Ellipsis Neurotherapeutics Inc. (“ENI”). Between November 4, 2004 and March 10, 2006, the Company acquired a 33.2% interest in ENI and the remaining 66.8% was acquired on March 10, 2006, all of which has been previously disclosed in Company press releases which were filed on the System for Electronic Document Analysis and Retrieval (SEDAR).
